SEC FORM 3

SEC FORM 3 SEC Form 3

FORM 3

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0104
Estimated average burden
hours per response:			0.5

1. Name and Address of Reporting Person^*

Temasek Holdings (Private) Ltd

(Last)

(First)

(Middle)

60B ORCHARD ROAD, #06-18

TOWER 2, THE ATRIUM@ORCHARD

(Street)

SINGAPORE

238891

(City)

(State)

(Zip)

2. Date of Event Requiring Statement (Month/Day/Year)
12/03/2021

3. Issuer Name and Ticker or Trading Symbol
Pear Therapeutics, Inc. [ PEAR ]

4. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

Director	X	10% Owner
Officer (give title below)		Other (specify below)

5. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

	Form filed by One Reporting Person
X	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Beneficially Owned
1. Title of Security (Instr. 4)	2. Amount of Securities Beneficially Owned (Instr. 4)	3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	4. Nature of Indirect Beneficial Ownership (Instr. 5)
Class A Common Stock	26,803,573	I	See footnotes⁽¹⁾⁽²⁾

Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 4)	2. Date Exercisable and Expiration Date (Month/Day/Year)		3. Title and Amount of Securities Underlying Derivative Security (Instr. 4)		4. Conversion or Exercise Price of Derivative Security	5. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	6. Nature of Indirect Beneficial Ownership (Instr. 5)
1. Title of Derivative Security (Instr. 4)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares	4. Conversion or Exercise Price of Derivative Security	5. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	6. Nature of Indirect Beneficial Ownership (Instr. 5)

1. Name and Address of Reporting Person^*

Temasek Holdings (Private) Ltd

(Last)

(First)

(Middle)

60B ORCHARD ROAD, #06-18

TOWER 2, THE ATRIUM@ORCHARD

(Street)

SINGAPORE

238891

(City)

(State)

(Zip)

1. Name and Address of Reporting Person^*

TLS Beta Pte. Ltd.

(Last)

(First)

(Middle)

60B ORCHARD ROAD #06-18

TOWER 2, THE ATRIUM@ORCHARD

(Street)

SINGAPORE

238891

(City)

(State)

(Zip)

1. Name and Address of Reporting Person^*

Temasek Life Sciences Private Ltd

(Last)

(First)

(Middle)

60B ORCHARD ROAD #06-18

TOWER 2, THE ATRIUM@ORCHARD

(Street)

SINGAPORE

238891

(City)

(State)

(Zip)

1. Name and Address of Reporting Person^*

Fullerton Management Pte Ltd

(Last)

(First)

(Middle)

60B ORCHARD ROAD #06-18

TOWER 2, THE ATRIUM@ORCHARD

(Street)

SINGAPORE

238891

(City)

(State)

(Zip)

1. Name and Address of Reporting Person^*

Elbrus Investments Pte. Ltd.

(Last)

(First)

(Middle)

60B ORCHARD ROAD #06-18

TOWER 2, THE ATRIUM@ORCHARD

(Street)

SINGAPORE

238891

(City)

(State)

(Zip)

Explanation of Responses:

1. The securities reported herein consist of 24,903,573 shares of Class A Common Stock of Pear Therapeutics, Inc. (the "Company") directly held by TLS Beta Pte. Ltd and 1,900,000 shares of Class A Common Stock of the Company directly held by Elbrus Investments Pte. Ltd.

2. Each of TLS Beta Pte. Ltd. and Elbrus Investments Pte. Ltd. is a direct wholly-owned subsidiary of Temasek Life Sciences Private Limited ("TLS"). TLS is a direct wholly-owned subsidiary of Fullerton Management Pte Ltd ("FMPL"), which in turn is a direct wholly-owned subsidiary of Temasek Holdings (Private) Limited. TLS, FMPL and Temasek Holdings (Private) Limited may therefore be deemed to have or share beneficial ownership of the securities held by each of TLS Beta Pte. Ltd. and Elbrus Investments Pte. Ltd. Each Reporting Owner disclaims beneficial ownership of such shares except to the extent of its pecuniary interest therein, and the inclusion of these securities in this report shall not be deemed an admission of beneficial ownership of the reported securities for purposes of Section 16 or for any other purposes.

Remarks:

	TLS Beta Pte. Ltd., By: /s/ Fidah Alsagoff, Authorised Signatory	12/09/2021
	Temasek Life Sciences Private Limited, By: /s/ Lim Siew Lee Sherlyn, Director	12/09/2021
	Fullerton Management Pte Ltd, By: /s/ Gregory Tan, Director	12/09/2021
	Elbrus Investments Pte. Ltd., By: /s/ Fidah Alsagoff, Authorised Signatory	12/09/2021
	Temasek Holdings (Private) Limited, By: /s/ Jason Norman Lee, Authorised Signatory	12/09/2021
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 5 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

SEC Form 3: New insider Temasek Holdings (Private) Ltd claimed ownership of 26,803,573 shares